Compare ASML & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASML | NVS |
|---|---|---|
| Founded | 1984 | 1895 |
| Country | Netherlands | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.4B | 254.8B |
| IPO Year | 1995 | 1991 |
| Metric | ASML | NVS |
|---|---|---|
| Price | $1,088.77 | $134.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $1,149.20 | $118.00 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 01-28-2026 | 01-30-2026 |
| Dividend Yield | 0.58% | ★ 1.96% |
| EPS Growth | ★ 37.86 | N/A |
| EPS | ★ 28.34 | 7.30 |
| Revenue | $37,666,043,037.00 | ★ $56,372,000,000.00 |
| Revenue This Year | $17.25 | $9.33 |
| Revenue Next Year | $4.64 | $2.75 |
| P/E Ratio | $38.14 | ★ $18.16 |
| Revenue Growth | ★ 22.77 | 12.88 |
| 52 Week Low | $578.51 | $96.06 |
| 52 Week High | $1,141.72 | $134.24 |
| Indicator | ASML | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 62.73 |
| Support Level | $1,077.19 | $131.77 |
| Resistance Level | $1,127.75 | $133.84 |
| Average True Range (ATR) | 26.55 | 1.63 |
| MACD | 0.73 | 0.27 |
| Stochastic Oscillator | 72.69 | 99.83 |
ASML is the leader in photolithography systems used in manufacturing semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's main clients are TSMC, Samsung, and Intel.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.